News Center

Home page

Peak Report

News reports

Jianfeng Group Pro 2015-007 (Jianfeng Group Daily Related Party Transaction Announcement)

Release time:

2020-08-05

Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Pro 2015-007

Bond Abbreviations: 13 Peak 01 Bond Code: 122227

Bond Abbreviations: 13 Peak 02 Bond Code: 122344

Zhejiang Jianfeng Group Co., Ltd.

Regular Related Party Transaction Announcement

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .

Basic Information of 1. Daily Related Party Transactions

Review Procedures for Implementation of (I) Daily Related Party Transactions

Jinhua Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinhua Pharmaceutical Company") purchases drugs from related party Tianjin Tianshili Pharmaceutical Marketing Group Co., Ltd. (hereinafter referred to as "Tianshili Marketing Group"). It is estimated that the purchase amount in 2015 will be between 0.5 and 5% of the company's audited net assets at the end of 2014 (no more than 103.0351 million yuan). Therefore, this related party transaction needs to be submitted to the board of directors for deliberation, but does not need to be submitted to the general meeting of shareholders for deliberation.

On April 17, 2015, the company held the second meeting of the ninth board of directors. All nine directors of the company attended the meeting in person. The related directors Mr. Jiang Xiaomeng and Mr. Du Zihong avoided voting on the proposal, which complied with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made were legal and effective. After deliberation and voting, the board of directors deliberated and passed the daily related party transaction proposal with 7 votes in favor, 0 votes against and 0 abstention.

The independent directors of the company reviewed the matter in advance and agreed to submit the proposal to the second meeting of the ninth board of directors of the company for deliberation. The independent directors of the company expressed their independent opinions on the adoption of the proposal by the board of directors, and believed that the formation of the resolution complied with the "Company Law", the company's "Articles of Association" and other relevant provisions, and did not harm the interests of small and medium shareholders.

Forecast and Implementation of (II)'s Last Daily Related Party Transaction

The Company issued a public announcement on April 15, 2014. It is estimated that the amount of drugs purchased by Jinhua Pharmaceutical Company from Tianshili Marketing Group in 2014 will be between 0.5 and 5% (between 8.685 million yuan and 86.8499 million yuan) of the Company's audited net assets at the end of 2013. The actual amount incurred in 2014 was 14.6314 million yuan, accounting for 2.13 percent of the amount of similar transactions, which did not exceed the expected range.

2. Related Party Introduction and Association Relationship

(I) the basic situation of related parties.

1. Jinhua Pharmaceutical Company: Established in January 1994, its domicile is located at 1180 Huancheng East Road, Jinhua City, its legal representative is Jin Xuecai, and its registered capital is 22 million yuan, of which: the company accounts for 10%, Zhejiang Jianfeng Pharmaceutical Co., Ltd., its holding subsidiary, accounts for 90%, and its main business is drug management. Wholesale and retail of prepackaged food; dangerous chemicals and medical devices; chemical reagents (except dangerous goods); glass and products; textiles, clothing and household daily necessities (except dangerous goods); fitness equipment supplies; computers, software and auxiliary equipment; wholesale and retail of teaching molds; exhibition services; medical information services; branches operate with valid certificates: purchase and processing of traditional Chinese medicine. The drug business license mainly includes: sales of proprietary Chinese medicines, Chinese medicinal materials, Chinese medicinal tablets, chemical preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic drugs, etc. The audited net profit for 2014 was 6.5056 million yuan, the net assets at the end of 2014 was 73.169 million yuan, and the liabilities were 237.9614 million yuan.

2, Tianshili Marketing Group: The company was established in 1999 February. The company's domicile is Tianshili Modern Chinese Medicine City, Xinyibai Avenue, Beichen Science and Technology Park, Tianjin, with its legal representative Yan Kaijing and registered capital of 25900 yuan, the business scope is the wholesale of Chinese herbal pieces, Chinese medicinal materials, Chinese patent medicines, chemical raw materials and their preparations, antibiotics, biochemical drugs, biological products, and diagnostic drugs; chemical raw materials ( except hazardous chemicals and precursor drugs ) , Wholesale and retail of cosmetics, daily chemical products, packaging materials and containers, plastic products, molds, and plastic raw materials; health food (hard capsules, soft capsules, granules, tablets, oral liquids, tea bags, health wine) wholesale and retail; disposable sterile syringes (needles), infusion sets (needles), corneal contact lenses and nursing solutions, medical polymer materials and products, physical therapy and rehabilitation equipment, medical hygiene materials and dressings, Chinese medicine equipment, general diagnosis equipment, Ward care equipment and appliances, household blood glucose meters and test strips, pregnancy diagnosis test strips, condoms wholesale; self-employed and agent of all kinds of goods and technology import and export business, but the state restricts the company to operate or prohibits the import and export of goods and technology, operating feed processing and "three to one supplement " business, operating trade and re-export trade, pre-packaged food wholesale and retail. The net profit attributable to the parent company in 2014 was 16,080.14 yuan, The net assets attributable to the parent company at the end of 2014 were 9,234.05 yuan, and the liabilities were 482,239.84 yuan.

The relationship between the (II) and the listed company

Because Tianshili Marketing Group is the holding subsidiary of Tianshili Pharmaceutical Group Co., Ltd., and Tianshili Pharmaceutical Group Co., Ltd. is the holding subsidiary of Tianshili Holding Group Co., Ltd. (hereinafter referred to as "Tianshili Group"), tasly Group is an associate of the Company and the Company has two directors who are also directors of Tasly Group, so Jinhua Pharmaceutical Company is related to Tasly Marketing Group.

(III) The amount of related party transactions in 2014 was 14.6314 million yuan, accounting for 2.13 percent of the amount of similar transactions. The implementation was good and there were no disputes.

Main Contents and Pricing Policy of 3. Related Party Transaction

Jinhua Pharmaceutical Company plans to continue to purchase drugs from Tianshili Marketing Group for sale this year. The main contents of this related party transaction are as follows:

(1) Transaction Target: Compound Danshen Dripping Pills, Yangxue Qingnao Granules, etc.

(2) Transaction Price: Agreement Price.

(3) settlement method: full payment according to the sales amount of last month.

(4) Agreement Validity Period: The validity period of the agreement signed by the above-mentioned related parties is 1 year from the date of signature by the legal representatives or authorized representatives of both parties.

(5) Other matters: If there is a major change in the content of this related party transaction during the implementation of the agreement, the company will disclose it in accordance with relevant regulations, and investors are requested to pay attention.

Purpose of 4. Related Party Transaction and Impact on Listed Companies

This related party transaction is to use Jinhua Pharmaceutical Company's existing sales network in Zhejiang Province to purchase drugs from Tianshili Marketing Group for distribution and sales, thus expanding Jinhua Pharmaceutical Company's business scope, further enhancing the Company's market influence and enhancing the Company's marketing capability. At the same time, Tasly Marketing Group is an indirect holding subsidiary of the Company's associates, and the expansion of its sales channels has increased the scale of corporate sales. The connected transaction will not harm the interests of the Company or the minority shareholders.

hereby announce

Zhejiang Jianfeng Group Co., Ltd.

Board of Directors

April 21, 2015

More information

Peak natural products among the top 20 scientific and technological innovation in TEDA

A few days ago, Tianjin Jianfeng Natural products Research and Development Co., Ltd. stood out among nearly 35000 enterprises in Tianjin Development Zone and won the honor of "Top 20 Scientific and technological Innovation Enterprises of 2015. The selection criteria for the top 20 scientific and technological innovation enterprises in Tianjin Economic and Technological Development Zone mainly include: they have won science and technology awards or patent awards in 2015, as well as other awards above the provincial level; they have obtained the qualification certification or approval of research and development institutions above the provincial level; in 2015, the number of invention and utility model patent applications and authorizations was large, totaling more than 15; in 2015, they were supported by national or Tianjin key science and technology plans; scientific research achievements have made significant progress and technology. According to the above standards, Jianfeng Natural Products Company has not only won the second prize of Tianjin Science and Technology Innovation Project Award for the achievements of "Tianjin Plant Waste Reutilization Technology Engineering Center Construction", but also completed the process research of grape seed extract and ginsenoside to pesticide residues, and formulated the international business standard of grape seed extract (grape seed oligomeric proanthocyanidins). In order to better carry out the pilot experiment, large-scale technical transformation was carried out on the second workshop, and the process optimization of extracting anthocyanins from blueberries has been carried out. At the same time, the main business income, operating profit, tax revenue and other economic indicators of peak natural products company in 2015 have increased significantly year-on-year. Relying on the advantages of excellent quality, good efficiency, great contribution, safety and environmental protection, and good social responsibility, Jianfeng Natural Products Company successfully passed the review and became one of the "Top 20 Scientific and Technological Innovation Enterprises in 2015" in Tianjin Development Zone. (

2020

07-31

Peak natural products among the top 20 scientific and technological innovation in TEDA

2020

07-30

Peak pharmaceutical "enterprise information construction project" through the acceptance

The "Enterprise Informatization Construction Project" of Jianfeng Pharmaceutical Company was included in the list of key projects of "Integration of Industrialization and Industrialization" (high-level and in-depth combination of informatization and industrialization) in Jinhua City in 2015, and successfully passed the on-site acceptance of the expert group on the morning of May 18. The main contents of the "enterprise information construction project" of the pharmaceutical company include: the tank farm control system, which solves the problem of closed metering and transportation of organic solvents between the tank farm and the production area, can automatically realize the terminal metering setting, and effectively ensure the safety and environmental protection requirements of the tank farm operation; The air conditioning automatic control system realizes the control of the temperature, humidity and room pressure difference in the air conditioning area through the PLC digital-to-analog conversion of the upper computer and lower computer and the terminal actuator regulator, ensure the cleanliness requirements of the production area environment; The online particle monitoring software system automatically adjusts to the standard flow through the upper computer, vacuum system, laser sensor and isodynamic sampling probe, etc. through the flow detector device and key orifice plate inside each sensor, monitors the temperature, humidity, particles, planktonian bacteria, room pressure difference, etc., implements dynamic management, and realizes visual monitoring of the production process environment. MRP production management system, it makes it easier for the warehouse, workshop, and management personnel to obtain information about the flow of materials in the production process, the implementation of production plans, and product inventory. During the on-site acceptance on the 18th, the acceptance team composed of the Information Department of the Municipal Economic and Information Commission, the Economic and Development Bureau of the Development Zone, the Municipal Information Promotion Association and professors of Zhejiang Normal University checked the contracts of each system software, purchase and transfer records, training records, and problem records in project implementation,

2020

07-31

Peak natural products among the top 20 scientific and technological innovation in TEDA

2020

07-31

< 1...58 59 60 61 > 跳转到页